Paratek publishes positive PhIII data on approved Nuzyra; Allergan settles opioid lawsuits in two Ohio counties
→ Paratek Pharmaceuticals‘ $PRTK Nuzyra (omadacycline) has met all primary and secondary clinical study endpoints in their OASIS-2 Phase III clinical trial, according to results published in The Lancet Infectious Diseases. In the study, involving 735 adults with ABSSSI, Nuzyra was shown to be as effective as Pfizer‘s $PFE twice-daily oral-only Zyvox (linezolid). Nuzyra is currently available in the US as a once-daily oral and intravenous antibiotic for the treatment of adults with community-acquired bacterial pneumonia and ABSSSI. The drug is also being studied for the treatment of urinary tract infections.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.